Respiratory

Hospital-acquired and ventilator-associated pneumonia: antibiotic selection

Clinical Overview and When to Suspect HAP/VAP

— HAP (hospital-acquired pneumonia): pneumonia occurring ≥48 hours after hospital admission, not incubating at admission, in a non-intubated patient

— VAP (ventilator-associated pneumonia): pneumonia developing >48 hours after endotracheal intubation

— HCAP is obsolete — the 2016 guidelines eliminated this category; nursing home/dialysis exposure alone no longer mandates broad-spectrum empiric therapy

— HAP is the most common nosocomial infection causing death in US hospitals

— VAP develops in ~10% of ventilated patients; attributable mortality 10–13%

— Each day of mechanical ventilation increases VAP risk by ~1–3%

— New or progressive radiographic infiltrate PLUS ≥2 of: fever >38°C, leukocytosis/leukopenia, purulent secretions, worsening oxygenation (declining PaO₂/FiO₂), increased ventilator support

— Sudden hemodynamic instability, new vasopressor need, or unexplained sepsis in a ventilated patient should trigger VAP workup

— Predominant organisms: Staphylococcus aureus (including MRSA), Pseudomonas aeruginosa, Enterobacterales (E. coli, Klebsiella, Enterobacter), Acinetobacter, Stenotrophomonas

— Anaerobes and atypicals (Legionella, Mycoplasma) play a much smaller role than in CAP

— Early-onset (<5 days): more likely community-type organisms (S. pneumoniae, MSSA, H. influenzae)

— Late-onset (≥5 days): higher risk of MDR Gram-negatives and MRSA

Board pearl: On Step 3, the trigger phrase "new infiltrate + fever + purulent secretions in an intubated patient on hospital day 6" should immediately push you toward empiric anti-pseudomonal + anti-MRSA coverage, not levofloxacin monotherapy. The instinct to default to CAP regimens is the most common wrong answer.

Definitions (2016 IDSA/ATS):

Epidemiology and importance:

When to suspect:

Key pathogen shift from CAP:

Timing classification (still useful):

Presentation Patterns and Key History

— Intubated ICU patient on day 5–10 develops fever, rising WBC, increased FiO₂ requirement, and purulent/changed-color tracheal secretions

— Nurse reports "more suctioning needed" or thicker, yellow-green sputum

— New rightward shift on chest X-ray with airspace opacity

— Post-op day 4 patient (especially after abdominal or thoracic surgery) with atelectasis trajectory who suddenly spikes a fever, develops productive cough, hypoxia, and a new infiltrate

— Stroke patient with dysphagia and witnessed aspiration episodes

— Days since admission/intubation (early vs late onset)

— Prior IV antibiotic use within 90 days — single strongest risk factor for MDR organisms per IDSA

— Local antibiogram — if your unit has >10–20% MRSA or >10% resistant Gram-negatives, broaden empirically

— Septic shock at time of VAP diagnosis — mandates dual Gram-negative coverage

— Structural lung disease (bronchiectasis, severe COPD, CF) — increases Pseudomonas probability

— Prior colonization with MRSA, ESBL, CRE, or Pseudomonas on surveillance cultures

— Altered mental status, seizures, recent extubation, NG tube, supine positioning, postoperative ileus, alcohol use disorder

— Note: routine anaerobic coverage is no longer recommended for aspiration pneumonia unless lung abscess or empyema present

— Recent water exposure, biofilm in ventilator circuit → consider Legionella

— Neutropenia, prolonged steroids, transplant → consider invasive aspergillosis, Pneumocystis

Key distinction: Recent IV antibiotic use within 90 days is the single most powerful predictor of MDR pathogens in HAP/VAP — even more than time-since-admission. A question stem mentioning "received ceftriaxone for UTI three weeks ago" is signaling you to broaden coverage.

Classic VAP presentation:

Classic non-ventilated HAP presentation:

Critical history elements — drive empiric coverage:

Aspiration-prone history:

Red flags for atypical etiologies:

Physical Exam Findings and Hemodynamic Assessment

— Focal crackles, bronchial breath sounds, or dullness to percussion over the affected lobe

— Decreased breath sounds if associated effusion or consolidation

— In ventilated patients, exam is often limited — rely on ventilator parameters: rising peak/plateau pressures, declining compliance, increased FiO₂ and PEEP requirements

— Fever (>38°C) or hypothermia (<36°C — ominous, sepsis physiology)

— Tachycardia, tachypnea (in non-intubated), rigors

— Altered mental status in elderly may be the only clue

— qSOFA ≥2 (RR ≥22, altered mentation, SBP ≤100): screen for sepsis

— SOFA score for ICU patients quantifies organ dysfunction

— New vasopressor requirement, lactate >2, oliguria → septic shock physiology

— Septic shock at VAP diagnosis mandates two anti-pseudomonal agents from different classes empirically

— PaO₂/FiO₂ ratio drop is the most sensitive early VAP indicator

— P/F <300 = ALI; <200 = moderate ARDS overlap; <100 = severe

— SpO₂/FiO₂ ratio is a non-invasive surrogate

— Asymmetric chest expansion, tracheal deviation → tension pneumothorax (barotrauma) or large empyema

— New murmur or peripheral stigmata → consider endocarditis with septic emboli mimicking pneumonia

— Subcutaneous emphysema → barotrauma or esophageal injury

CCS pearl: In a CCS case of suspected VAP, order in this sequence: vital signs and pulse oximetry → arterial blood gas → portable chest X-ray → blood cultures ×2 → lower respiratory tract sample (endotracheal aspirate or BAL) → CBC, BMP, lactate → then start empiric antibiotics within 1 hour. Do not delay antibiotics waiting for cultures in septic patients.

Respiratory exam:

Systemic signs:

Hemodynamic assessment — drives disposition and antibiotic breadth:

Oxygenation indices:

Look for complication clues on exam:

Diagnostic Workup — Initial Labs, Imaging, Biomarkers

— Portable AP chest X-ray is the standard initial study — look for new or progressive infiltrate, air bronchograms, lobar consolidation, cavitation

— Limitations: poor sensitivity in supine ICU patients; ARDS, pulmonary edema, atelectasis, and hemorrhage all mimic pneumonia

— CT chest if X-ray equivocal, suspected abscess/empyema, or non-resolving infection

— Lung ultrasound increasingly used at bedside — high sensitivity for consolidation and effusion

— CBC with differential — leukocytosis with left shift or leukopenia

— BMP, LFTs, lactate — assess organ dysfunction

— ABG — quantify hypoxemia, acid-base status

— Blood cultures ×2 from separate sites before antibiotics (positive in ~15% of HAP/VAP but identify bacteremic cases needing longer therapy)

— Non-invasive: endotracheal aspirate (preferred per 2016 IDSA) with semi-quantitative culture

— Invasive: bronchoalveolar lavage (BAL, threshold ≥10⁴ CFU/mL), protected specimen brush (PSB, ≥10³ CFU/mL)

— 2016 guidelines: non-invasive sampling with semi-quantitative cultures preferred — less morbidity, comparable outcomes

— Gram stain helps narrow empiric choices (e.g., Gram-positive cocci in clusters → keep anti-MRSA)

— Procalcitonin (PCT): not for diagnosis but useful for de-escalation/duration — declining PCT supports stopping antibiotics

— CRP — nonspecific, not recommended as standalone

— Do not use PCT alone to withhold antibiotics in suspected VAP

— Legionella urinary antigen if epidemiologic clues; Streptococcus pneumoniae antigen lower yield in HAP

Board pearl: Always obtain respiratory cultures BEFORE starting empiric antibiotics — but never delay antibiotics in unstable patients more than briefly to do so. Cultures guide critical de-escalation 48–72 hours later, which is the highest-yield Step 3 management step.

Chest imaging:

Laboratory studies:

Lower respiratory tract sampling — required before empiric therapy when feasible:

Biomarkers:

Urinary antigens:

Diagnostic Workup — Advanced and Confirmatory Studies

— Failure to respond to empiric therapy at 72 hours

— Immunocompromised host (transplant, neutropenia, advanced HIV) — broader differential including PCP, CMV, fungi, mycobacteria

— Suspected unusual pathogens or resistant organisms

— Need to rule out non-infectious mimics (alveolar hemorrhage, ARDS, drug toxicity, organizing pneumonia)

— Quantitative bacterial culture with thresholds (≥10⁴ CFU/mL)

— Fungal smear and culture

— AFB smear and culture if risk factors

— Galactomannan (Aspergillus), beta-D-glucan (broad fungal incl. PCP)

— PCR for respiratory viruses (influenza, RSV, SARS-CoV-2)

— PCP PCR or DFA in immunocompromised

— Cytology if malignancy suspected

— Multiplex PCR panels (e.g., BioFire Pneumonia Panel) detect 15+ bacteria and resistance genes (mecA, KPC, NDM, CTX-M) in ~1 hour

— Allow earlier targeted therapy and de-escalation

— Caveat: detection of organism DNA does not prove infection vs colonization — interpret with clinical context

— New parapneumonic effusion → diagnostic thoracentesis if >1 cm on lateral decubitus or any loculation

— Send pH, glucose, LDH, protein, Gram stain, culture, cell count

— Complicated parapneumonic effusion / empyema (pH <7.2, glucose <40, positive Gram stain or pus) → chest tube drainage

— TTE if persistent bacteremia (especially S. aureus) — rule out endocarditis

— TEE if TTE non-diagnostic and clinical suspicion remains

Step 3 management: If a VAP patient is not improving by day 3 on appropriate empiric therapy, the next step is bronchoscopy with BAL plus CT chest — not simply broadening antibiotics. Look for empyema, abscess, resistant organism, or alternative diagnosis (PE, ARDS, drug fever).

When to escalate to bronchoscopy with BAL:

BAL studies to send:

Rapid molecular diagnostics (increasingly used):

Pleural effusion workup:

Echocardiography:

Risk Stratification and Empiric Coverage Logic

— Risk factors: IV antibiotics within 90 days, hospitalization in a unit where >10–20% of S. aureus is MRSA, MRSA colonization, prior MRSA infection

— Yes → add vancomycin or linezolid

— No → cover MSSA only with a single agent (piperacillin-tazobactam, cefepime, levofloxacin)

— Risk factors: IV antibiotics within 90 days, septic shock at VAP onset, ARDS preceding VAP, ≥5 days of hospitalization before VAP, acute renal replacement therapy before VAP, structural lung disease, known colonization

— Yes → use two anti-pseudomonal agents from different classes

— No → single anti-pseudomonal agent sufficient

— Need for ventilatory support due to pneumonia or septic shock → automatically use double Gram-negative coverage

— Low MDR risk, not high mortality risk: single agent covering MSSA + Pseudomonas (pip-tazo, cefepime, levofloxacin, imipenem, meropenem)

— High MRSA risk: add vancomycin/linezolid

— High MDR Gram-negative risk OR high mortality risk: two anti-pseudomonal agents + MRSA coverage

— Always tailor to your hospital's resistance patterns

— If >10% Gram-negative resistance to monotherapy agent → use combination empirically

Key distinction: Double Gram-negative coverage in VAP is for empiric breadth (covering the gap between two classes), not for synergy. Once cultures return, de-escalate to monotherapy with the most narrow-spectrum effective agent — this is a frequent Step 3 stem testing antimicrobial stewardship.

Three-question algorithm (2016 IDSA/ATS) — drives every empiric choice:

Question 1: Risk for MRSA?

Question 2: Risk for MDR Pseudomonas / Gram-negatives?

Question 3: Mortality risk / septic shock?

HAP (non-VAP) simplified empiric tiers:

Local antibiogram is decisive:

Pharmacotherapy — First-Line Empiric Regimens

— Vancomycin 15–20 mg/kg IV q8–12h, target AUC₂₄ 400–600 mg·h/L (or trough 15–20 mg/L if AUC unavailable); loading dose 25–30 mg/kg in severe disease

— Linezolid 600 mg IV/PO q12h — preferred if vancomycin MIC ≥2, renal failure, or concern for vancomycin-induced AKI; superior tissue penetration in some studies but watch for thrombocytopenia, serotonin syndrome with SSRIs

— Daptomycin is NOT used for pneumonia (inactivated by surfactant)

— Piperacillin-tazobactam 4.5 g IV q6h (extended infusion preferred)

— Cefepime 2 g IV q8h

— Ceftazidime 2 g IV q8h (no Gram-positive coverage, rarely first-line alone)

— Meropenem 1 g IV q8h or imipenem 500 mg IV q6h — reserve for ESBL risk or carbapenem-required cases

— Aztreonam 2 g IV q8h — for severe beta-lactam allergy

— Levofloxacin 750 mg IV/PO daily or ciprofloxacin 400 mg IV q8h

— Tobramycin/amikacin/gentamicin — aminoglycosides; nephrotoxic, less ideal alone (poor lung penetration) but acceptable as second agent

— Avoid two beta-lactams together (no benefit, increased toxicity)

— Ceftolozane-tazobactam or ceftazidime-avibactam for MDR Pseudomonas, ESBL, some CRE

— Meropenem-vaborbactam, imipenem-relebactam for KPC-producing CRE

— Cefiderocol for highly resistant Gram-negatives including Stenotrophomonas, Acinetobacter

— Polymyxins (colistin) — last resort, nephrotoxic; consider inhaled adjunct for MDR

Step 3 management: Reassess at 48–72 hours with culture data. De-escalate to narrowest effective agent, shorten to 7 days total for most HAP/VAP (per 2016 guidelines and PneumA trial) — longer only for non-fermenting GNR with poor clinical response, immunocompromise, empyema, or bacteremia with S. aureus.

Anti-MRSA agents (choose one):

Anti-pseudomonal beta-lactams (choose one or two):

Second anti-pseudomonal (non-beta-lactam) for double coverage:

Resistant organism agents (consult ID, antibiogram-driven):

Timing: Administer first dose within 1 hour of suspected sepsis; delay increases mortality ~7% per hour.

Pathogen-Directed Therapy and De-Escalation

— Within 48–72 hours, narrow based on culture, susceptibilities, and clinical response

— Stop MRSA coverage if cultures negative for MRSA and patient improving

— Stop double Gram-negative coverage once susceptibility known — keep the single most narrow active agent

— Switch to PO when patient tolerating diet, hemodynamically stable, and oral bioavailability adequate

— MSSA: nafcillin, oxacillin, or cefazolin (preferred for bacteremia, better tolerated); NOT vancomycin (inferior)

— MRSA: vancomycin or linezolid

— Pseudomonas aeruginosa (susceptible): monotherapy with pip-tazo, cefepime, meropenem, or levofloxacin based on susceptibility

— ESBL-producing Enterobacterales: carbapenem (meropenem) is first-line for serious infection; pip-tazo not reliable

— CRE (KPC): ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam

— CRE (NDM, OXA-48): ceftazidime-avibactam ± aztreonam, or cefiderocol

— Acinetobacter baumannii: ampicillin-sulbactam (high dose), cefiderocol, or polymyxins for MDR strains

— Stenotrophomonas maltophilia: TMP-SMX is first-line; alternatives include levofloxacin, minocycline, cefiderocol

— Legionella: azithromycin or levofloxacin

— Anaerobes (only if lung abscess/empyema): ampicillin-sulbactam, pip-tazo, or metronidazole add-on

— 7 days for most HAP/VAP (Class I, Level A recommendation)

— Extend if: empyema, lung abscess, necrotizing pneumonia, immunocompromise, slow clinical response, S. aureus bacteremia (2–6 weeks based on complications)

— Use procalcitonin trajectory to support discontinuation in select cases

— Adjunctive nebulized colistin or tobramycin considered for MDR Gram-negative VAP not responding to systemic therapy — controversial, not routine

Board pearl: A culture growing MSSA should immediately trigger a switch from vancomycin to cefazolin or nafcillin — vancomycin is inferior for MSSA and is a common wrong-to-right answer pivot on Step 3.

De-escalation principles (highest-yield Step 3 stewardship concept):

Pathogen-specific preferred therapy:

Duration of therapy:

Inhaled antibiotics:

Special Populations — Elderly, Renal, and Hepatic Impairment

— Higher baseline mortality, frailty, and polypharmacy

— Atypical presentations: delirium or falls may dominate over fever

— Avoid fluoroquinolones when alternatives exist — increased risk of tendinopathy, QT prolongation, C. difficile, aortic dissection, delirium

— Beers Criteria caution with aminoglycosides (nephrotoxicity, ototoxicity)

— Goals-of-care discussion early — VAP in elderly with multiple comorbidities has very high mortality

— Vancomycin: pharmacy-driven AUC monitoring; reduce frequency in CKD

— Piperacillin-tazobactam: reduce to 3.375 g q6h or q8h based on CrCl

— Cefepime: dose-adjust below CrCl 60; cefepime neurotoxicity (encephalopathy, myoclonus, non-convulsive status) is a classic exam pearl in renal failure

— Meropenem: reduce dose/frequency below CrCl 50; carbapenem-induced seizures more common in renal failure, elderly, and CNS pathology

— Aminoglycosides: extended-interval dosing with levels; avoid in AKI

— Levofloxacin: dose-adjust below CrCl 50

— Linezolid: no renal adjustment — favored option in dialysis

— Many beta-lactams cleared by dialysis → time doses post-HD or increase frequency on CRRT

— Vancomycin and aminoglycosides require level-based dosing on CRRT

— Most anti-pneumonia antibiotics are renally cleared and safe in liver disease

— Tigecycline, linezolid require caution in severe hepatic disease

— Avoid hepatotoxic combinations; monitor LFTs with prolonged courses

— Linezolid + SSRIs/MAOIs → serotonin syndrome

— Fluoroquinolones + warfarin → INR elevation

— Carbapenems + valproate → drops valproate levels, seizure risk

Board pearl: Cefepime-induced neurotoxicity in a CKD patient presenting with new confusion, myoclonus, or seizures is a high-yield Step 3 vignette. Treatment: stop cefepime, switch to an alternative; dialysis may accelerate clearance.

Elderly considerations:

Renal dose adjustments:

Renal replacement therapy:

Hepatic impairment:

Drug interactions in polypharmacy:

Special Populations — Pregnancy, Pediatrics, Immunocompromised

— HAP in pregnancy is rare but high-stakes; treat aggressively

— Safe: beta-lactams (penicillins, cephalosporins, carbapenems), azithromycin, vancomycin, clindamycin

— Avoid when possible: fluoroquinolones (cartilage concerns — though increasingly used when benefit outweighs risk), tetracyclines (after first trimester — teeth, bone), aminoglycosides (ototoxicity, nephrotoxicity to fetus)

— TMP-SMX: avoid in first trimester (neural tube defects via folate antagonism) and near term (kernicterus risk)

— Linezolid: limited data, use only if benefit justifies risk

— Maintain maternal SpO₂ ≥95% — fetal oxygenation depends on maternal PaO₂

— VAP pathogens shift toward Pseudomonas, S. aureus (including MRSA), and respiratory viruses

— Empiric: vancomycin + anti-pseudomonal beta-lactam, similar logic to adults

— Avoid fluoroquinolones and tetracyclines when alternatives exist (age-related restrictions)

— Weight-based dosing essential

— Broaden differential: Pneumocystis jirovecii (steroids, HIV CD4 <200, transplant), invasive aspergillosis (prolonged neutropenia, hematologic malignancy, lung transplant), CMV (transplant), Nocardia, mycobacteria

— Empiric coverage may add: TMP-SMX (PCP), voriconazole or isavuconazole (Aspergillus), ganciclovir (CMV)

— Lower threshold for bronchoscopy with BAL early

— Galactomannan, beta-D-glucan, viral PCRs essential

— Treat as neutropenic fever with pneumonia — anti-pseudomonal beta-lactam ± vancomycin ± antifungal if persistent fever

— Consult heme/onc and ID

— Tacrolimus/cyclosporine interactions with macrolides, fluoroquinolones — monitor levels

— Consider rejection and drug toxicity in differential

Key distinction: A neutropenic patient (ANC <500) with new pulmonary infiltrate is not just HAP — it's febrile neutropenia with pneumonia, requiring immediate empiric anti-pseudomonal coverage plus consideration of fungal pathogens, often before culture data return.

Pregnancy:

Pediatrics (Step 3 — limited but tested):

Immunocompromised hosts:

Neutropenic febrile patient with pneumonia:

Solid organ and stem cell transplant:

Complications and Adverse Outcomes

— Parapneumonic effusion / empyema: drainage required if pH <7.2, glucose <40, positive Gram stain or pus; tube thoracostomy ± intrapleural tPA/DNase; surgical decortication if loculated

— Lung abscess: prolonged antibiotics (4–6 weeks), drainage if large or not responding; cover anaerobes

— Necrotizing pneumonia: classic with S. aureus (especially PVL-positive), Klebsiella, Pseudomonas — high mortality

— Bronchopleural fistula: especially after necrotizing infection or barotrauma

— ARDS: new bilateral infiltrates, P/F <300, not explained by cardiac failure — supportive lung-protective ventilation (6 mL/kg IBW, plateau <30, prone positioning if P/F <150)

— Septic shock: vasopressors, lactate-guided resuscitation, early antibiotics

— Bacteremia / metastatic seeding: S. aureus → endocarditis, vertebral osteomyelitis, septic arthritis; mandate TTE and prolonged therapy

— Multi-organ dysfunction: AKI, hepatic dysfunction, DIC

— Clostridioides difficile colitis: broad-spectrum antibiotics, especially fluoroquinolones, clindamycin, cephalosporins

— Acute kidney injury: vancomycin, aminoglycosides, piperacillin-tazobactam + vancomycin combination (controversial but signal of additive nephrotoxicity)

— Drug fever, rash, DRESS: beta-lactams, vancomycin (red man syndrome with rapid infusion, distinct from anaphylaxis)

— Cytopenias: linezolid-induced thrombocytopenia (>10–14 days), vancomycin-induced neutropenia

— Prolonged ventilation, ICU-acquired weakness, post-intensive care syndrome

— Tracheostomy may become necessary if intubation >14 days

— Septic shock, inappropriate initial antibiotics, MDR pathogens, comorbidities, late-onset, age, ARDS

Board pearl: S. aureus bacteremia in a VAP patient mandates TTE (and TEE if TTE negative), source control, and at least 2 weeks of IV therapy (4–6 weeks if complicated). Missing endocarditis evaluation in S. aureus bacteremia is a classic Step 3 trap.

Pulmonary complications:

Systemic complications:

Treatment-related complications:

Mechanical ventilation complications compounded by VAP:

Mortality predictors:

When to Escalate Care — ICU, Consult, Inpatient Triage

— Septic shock requiring vasopressors

— Acute respiratory failure requiring mechanical ventilation or high-flow >15 L/min

— Multi-lobar involvement with hypoxemia

— Altered mental status from hypoxia or sepsis

— Lactate >2, worsening organ dysfunction

— Apply IDSA/ATS severe CAP criteria as a framework (1 major or ≥3 minor)

— Vital signs q1h, continuous telemetry, SpO₂

— Two large-bore IVs, arterial line if vasopressors

— Crystalloid bolus 30 mL/kg if septic shock

— Empiric antibiotics within 1 hour

— Lactate q2h until clearing

— Foley for urine output monitoring

— Lung-protective ventilation if intubated

— Stress ulcer prophylaxis (PPI/H2 blocker), VTE prophylaxis

— Daily sedation interruption ("sedation vacation") and spontaneous breathing trial assessment

— Pulmonary/critical care for ventilator management and bronchoscopy

— Infectious disease for MDR pathogens, immunocompromised, complicated cases, antimicrobial stewardship

— Thoracic surgery for empyema requiring decortication, lung abscess not responding

— Interventional radiology for image-guided drainage of empyema or abscess

— Nephrology if AKI requiring RRT

— Nutrition — early enteral feeding within 24–48 hours

— Head of bed 30–45°

— Daily sedation interruption and SBT readiness assessment

— Oral care with chlorhexidine (controversial in recent data)

— DVT and stress ulcer prophylaxis

— Subglottic suctioning ET tubes for anticipated ventilation >48 hours

— Hemodynamically stable off vasopressors ≥24h

— Adequate oxygenation on non-ventilator support

— Improving inflammatory markers and clinical status

Step 3 management: A non-ventilated HAP patient who develops rising oxygen requirement and altered mentation on the floor should trigger rapid response activation and early ICU transfer — do not wait for frank intubation criteria. Delayed ICU transfer is a recurring patient safety theme.

ICU admission criteria (severe HAP or any VAP by definition):

CCS pearl — initial ICU orders sequence:

Consults to order:

VAP prevention bundle ("ventilator bundle") — order on every ventilated patient:

Step-down/floor transfer criteria:

Key Differentials — Other Pulmonary Infections

— Symptoms began before hospitalization or within first 48 hours

— Pathogens: S. pneumoniae, H. influenzae, M. pneumoniae, Legionella, viruses

— Treat per CAP guidelines (ceftriaxone + macrolide, or respiratory fluoroquinolone)

— Key distinction: the timing of pneumonia onset relative to admission determines HAP vs CAP — and therefore empiric breadth

— Pneumonitis: chemical injury from gastric acid; rapid onset hypoxia within hours; often improves in 24–48h without antibiotics

— Pneumonia: bacterial superinfection developing 48–72h later

— Routine anaerobic coverage no longer recommended unless abscess/empyema/severe periodontal disease

— Right lower lobe (or right upper lobe if supine) classic location

— Purulent secretions, fever, leukocytosis without new infiltrate

— May progress to VAP; antibiotic treatment of VAT is controversial — some evidence reduces progression to VAP

— Risk factors: incarceration, homelessness, HIV, immigration from endemic areas

— Upper lobe cavitation, weight loss, night sweats, chronic cough

— Isolate immediately in negative pressure room; send AFB smears ×3, NAAT

— MAC, M. abscessus — chronic indolent course, bronchiectasis, elderly women ("Lady Windermere")

— Influenza, RSV, SARS-CoV-2, adenovirus — diffuse ground-glass, bilateral

— Send respiratory viral PCR panel

— Consider oseltamivir empirically during flu season

— Aspergillus (immunocompromised, halo sign on CT), endemic mycoses (histoplasma, coccidioides, blastomyces), Pneumocystis (HIV/immunosuppression)

Board pearl: A vignette with purulent secretions and fever but a clear chest X-ray in a ventilated patient is ventilator-associated tracheobronchitis (VAT), not VAP. This distinction matters — VAP requires a new infiltrate radiographically.

Community-acquired pneumonia (CAP):

Aspiration pneumonitis vs aspiration pneumonia:

Ventilator-associated tracheobronchitis (VAT):

Pulmonary tuberculosis or reactivation:

Nontuberculous mycobacteria (NTM):

Viral pneumonia:

Fungal pneumonia:

Key Differentials — Non-Infectious Mimics

— Sudden hypoxia, tachycardia, possibly pleuritic pain; may have low-grade fever

— Risk factors: immobility, surgery, malignancy, hypercoagulability, prior VTE

— Key distinction: PE often has clear lungs on chest X-ray despite severe hypoxia (V/Q mismatch); D-dimer not useful in hospitalized patients (low specificity); CT pulmonary angiogram is diagnostic

— Treat empirically with anticoagulation if high pretest probability while awaiting imaging

— Bilateral infiltrates from sepsis (non-pulmonary), pancreatitis, transfusion (TRALI), aspiration, trauma, drug toxicity

— Berlin criteria: acute onset <1 week, bilateral opacities, not explained by cardiac failure, P/F ≤300

— Bilateral perihilar infiltrates, Kerley B lines, cephalization, cardiomegaly, effusions

— Elevated BNP, echocardiographic evidence of reduced LV function or diastolic dysfunction

— Diuresis improves clinical picture rapidly — pneumonia does not

— Common postoperatively; volume loss with mediastinal shift toward affected side; usually responds to chest physiotherapy and incentive spirometry — distinguishes from consolidation

— Hemoptysis (may be absent), dropping hemoglobin, bilateral infiltrates; BAL with sequentially bloodier aliquots and hemosiderin-laden macrophages

— Causes: vasculitis (ANCA-associated), anticoagulation, mitral stenosis, drug-induced

— Amiodarone, methotrexate, nitrofurantoin, bleomycin, immune checkpoint inhibitors

— Temporal relationship to drug initiation; resolution with discontinuation ± steroids

— Subacute cough, fever, migratory consolidations not responding to antibiotics

— Diagnosis via biopsy; treatment with corticosteroids

Step 3 management: A patient with "pneumonia" not responding to broad-spectrum antibiotics by day 5–7 should prompt reconsideration of the diagnosis with CT chest, bronchoscopy, and assessment for non-infectious mimics — particularly PE, DAH, COP, and drug-induced injury. Reflexively broadening antibiotics is the wrong answer.

Pulmonary embolism:

ARDS (non-pneumonia causes):

Cardiogenic pulmonary edema / volume overload:

Atelectasis:

Diffuse alveolar hemorrhage (DAH):

Drug-induced lung injury / pneumonitis:

Cryptogenic organizing pneumonia (COP):

Acute eosinophilic pneumonia, hypersensitivity pneumonitis, malignancy, lymphangitic carcinomatosis — consider in non-resolving cases

Secondary Prevention and Discharge Planning

— Head of bed elevation 30–45° unless contraindicated

— Daily sedation interruption and spontaneous breathing trial to minimize ventilator days

— Subglottic secretion drainage ET tubes for anticipated ventilation >48–72h

— Oral care protocols (chlorhexidine use evolving)

— Hand hygiene compliance, contact precautions for MDR colonization

— Early mobilization, even of ventilated patients

— Bedside swallow screen before oral intake post-stroke, post-extubation, in dysphagia

— Speech-language pathology evaluation, modified diet textures

— Avoid unnecessary sedation in elderly

— Consider PEG over NG for prolonged dysphagia (after 2–4 weeks, individualized)

— Complete prescribed antibiotic course (typically 7 days total) — most patients finish IV inpatient; PO completion if bioavailable agent and stable

— Reconcile with home medication list; stop pre-admission antibiotics no longer indicated

— Provide clear written instructions on completion dates and follow-up

— Pneumococcal: PCV20 (or PCV15 followed by PPSV23) for age ≥65 or high-risk adults; update per current ACIP recommendations

— Influenza: annually for all ≥6 months

— COVID-19: per current schedule

— RSV: for adults ≥75 (and 60–74 with high risk) per ACIP

— Every hospitalization is a teachable moment; offer nicotine replacement, varenicline, bupropion; counseling

— Reduces future pneumonia, COPD exacerbation, and cardiovascular risk

— Optimize chronic disease (COPD inhalers, CHF management, diabetes glycemic control)

— Nutrition assessment — malnutrition increases infection risk

— Reduce unnecessary PPI use (associated with pneumonia risk)

Board pearl: Pneumococcal vaccination at discharge is a frequently missed quality measure — ensure it's ordered before transfer/discharge if patient is age-eligible or has chronic comorbidities. Step 3 quality/safety stems love this.

HAP/VAP prevention bundles — primary prevention is the priority:

Aspiration risk reduction:

Discharge medications and transitions:

Vaccinations before discharge (do not miss):

Smoking cessation:

Address modifiable risk factors:

Follow-Up, Monitoring, and Rehabilitation

— Daily clinical assessment: fever curve, oxygenation, ventilator parameters, mentation

— Daily CBC, BMP; LFTs every 2–3 days

— Vancomycin AUC or trough monitoring; aminoglycoside levels

— Repeat lactate until normalized

— Daily chest X-ray in ventilated patients (or as clinically indicated — moving toward less routine imaging)

— Consider repeat procalcitonin to support de-escalation

— Clinical improvement typically by 48–72 hours: defervescence, decreasing oxygen requirement, improving WBC

— Radiographic improvement lags clinical response by days to weeks — do not chase imaging

— Persistent fever or worsening at 72h → reassess: wrong pathogen, wrong drug, complication, alternative diagnosis

— Primary care follow-up within 1–2 weeks post-discharge

— Repeat chest imaging at 6–8 weeks if age ≥50, smoker, or persistent symptoms — screen for underlying malignancy (post-obstructive pneumonia)

— Assess functional status, return to baseline activity

— Medication reconciliation

— Post-ICU syndrome: cognitive impairment, weakness, PTSD/anxiety/depression — screen at follow-up

— Pulmonary rehabilitation for patients with persistent dyspnea, COPD, prolonged ventilation

— Physical therapy for deconditioning; occupational therapy for ADLs

— Cognitive screening (MoCA) in elderly with delirium during hospitalization

— Increased risk of recurrent pneumonia, especially with structural lung disease, dysphagia, immunocompromise

— Discuss advance directives, goals of care — particularly after ICU stay

— Mental health support; consider ICU diary review

— Tracheal stenosis after prolonged intubation — evaluate for stridor, dyspnea

— Recurrent aspiration in stroke/neurodegenerative disease

Step 3 management: A patient age ≥50 with HAP should get a follow-up chest X-ray at 6–8 weeks to confirm radiographic resolution — non-resolution warrants CT chest and bronchoscopy to rule out underlying malignancy or endobronchial lesion. This is a frequently tested longitudinal management point.

Inpatient monitoring parameters during therapy:

Response assessment timeline:

Post-discharge follow-up:

Rehabilitation considerations:

Long-term outcomes counseling:

Monitoring for late complications:

Ethical, Legal, and Patient Safety Considerations

— VAP in patients with advanced cancer, end-stage organ disease, or severe dementia carries very high mortality

— Early palliative care consultation in prolonged ICU stays improves family communication and may reduce non-beneficial interventions

— Surrogate decision-makers may differ in interpretation of patient wishes; clarify advance directives early, ideally before crisis

— Time-limited trials of aggressive therapy (e.g., 72-hour reassessment) help structure decisions

— Bronchoscopy, central line placement, tracheostomy require informed consent — obtain from patient if capacitated, otherwise legal surrogate

— Emergent procedures (e.g., emergency intubation) proceed under emergency exception when surrogate unavailable

— Document capacity assessment when consent is contested

— Unnecessary broad-spectrum antibiotics drive resistance, C. difficile, AKI

— Daily review of antibiotic indication, narrowing, and stop date is a Joint Commission and CMS quality measure

— Mandatory de-escalation review at 48–72 hours is now embedded in many hospital protocols

— Medication reconciliation errors at discharge are common — antibiotic durations, renal dose adjustments, drug interactions

— Communicate pending culture results and follow-up plan to receiving provider (PCP, SNF)

— Use structured handoff (e.g., I-PASS, SBAR) to reduce omission errors

— CMS Hospital-Acquired Condition Reduction Program — VAP and CLABSI rates affect reimbursement

— Report MDR organisms (CRE, MRSA outbreaks) to infection control per institutional policy

— Public health reporting for TB if identified

— Isolation precautions: contact precautions for MDR colonization, airborne for TB

— Ventilator bundle adherence audited; non-compliance is a system failure, not individual failing

— Root cause analysis for sentinel VAP-related deaths

— Disparities in ICU admission, antibiotic appropriateness, and outcomes by race/insurance — institutional review increasingly required

Board pearl: When a question stem describes a patient discharged on IV antibiotics to a SNF without communication to the receiving facility, the patient safety answer is "ensure structured handoff with documentation of pending results, antibiotic duration, and follow-up plan" — not simply continuing therapy.

Goals of care and end-of-life discussions:

Informed consent for procedures:

Antimicrobial stewardship as a safety issue:

Transition-of-care risk (highest-yield Step 3 patient safety theme):

Mandatory reporting and infection control:

Patient safety bundles:

Equity considerations:

High-Yield Associations and Rapid-Fire Facts

— Cavitating pneumonia in IVDU or post-influenza: S. aureus (especially MRSA, PVL-positive)

— Currant jelly sputum, upper lobe cavitation, alcoholic: Klebsiella pneumoniae

— Burn unit or ICU with green sputum, ecthyma gangrenosum: Pseudomonas aeruginosa

— CF or bronchiectasis exacerbation: Pseudomonas, Burkholderia cepacia, S. aureus

— Recent water exposure, hyponatremia, diarrhea, transaminitis: Legionella

— Bilateral interstitial infiltrates in HIV with CD4 <200: Pneumocystis jirovecii

— Halo sign or air crescent in neutropenic patient: invasive aspergillosis

— Lung abscess with foul-smelling sputum, poor dentition: anaerobes

— Daptomycin inactivated by surfactant — never for pneumonia

— Tigecycline: FDA black box warning for increased mortality in VAP — avoid as monotherapy

— Linezolid + serotonergic drugs → serotonin syndrome

— Cefepime in CKD → neurotoxicity (confusion, myoclonus, NCSE)

— Vancomycin + pip-tazo → additive nephrotoxicity (signal in retrospective data)

— Carbapenems + valproate → drop valproate levels, breakthrough seizures

— Fluoroquinolones: tendinopathy, aortic dissection, QT, dysglycemia, C. diff, delirium

— 7 days for most HAP/VAP

— 2 weeks minimum for S. aureus bacteremia, longer if complicated

— 4–6 weeks for lung abscess or empyema with retained collection

— Extend non-fermenter (Pseudomonas, Acinetobacter) only if slow response, otherwise 7 days OK

— HOB 30–45°, sedation vacations, SBT daily, oral care, subglottic suctioning, early mobility, hand hygiene

— 48 hours: HAP/VAP onset threshold

— 90 days: prior IV antibiotic window for MDR risk

— 5 days: late-onset HAP/VAP threshold

— 10–20%: local MRSA threshold for empiric vancomycin

— 1 hour: empiric antibiotic timing in sepsis

Board pearl: "Post-influenza necrotizing pneumonia with cavitation" = think MRSA (community-acquired, PVL-positive) — empirically cover with vancomycin or linezolid plus an anti-staphylococcal beta-lactam.

Pathogen-clue pattern recognition:

Drug pearls:

Duration pearls:

VAP prevention quick hits:

Guideline-defining numbers:

Board Question Stem Patterns

— ICU day 7, intubated, new infiltrate, purulent secretions, fever, rising FiO₂; received ceftriaxone before admission for UTI

— Answer: vancomycin + (cefepime or pip-tazo) + (levofloxacin or aminoglycoside) — double Gram-negative because of prior antibiotic + late-onset risk

— VAP started on vancomycin + cefepime + tobramycin; day 3, BAL grows pan-susceptible E. coli; patient improving

— Answer: stop vancomycin and tobramycin, continue cefepime monotherapy — antimicrobial stewardship priority

— Patient on vancomycin for VAP; cultures return MSSA susceptible to oxacillin

— Answer: switch to cefazolin or nafcillin — vancomycin inferior for MSSA

— CKD patient on cefepime develops confusion, myoclonus, possible seizure

— Answer: discontinue cefepime, consider dialysis; switch to alternative agent

— HAP on appropriate antibiotics × 5 days, persistent fever, expanding infiltrate

— Answer: CT chest + bronchoscopy with BAL to evaluate for empyema, abscess, resistant organism, or alternative diagnosis (PE, COP, malignancy)

— HAP patient with new pleural effusion; thoracentesis shows pH 7.0, glucose 30, positive Gram stain

— Answer: chest tube drainage in addition to antibiotics; consider intrapleural tPA/DNase if loculated

— Uncomplicated VAP, clinically improved on day 7

— Answer: stop antibiotics at 7 days — not 14, not "until afebrile 48h"

— Witnessed aspiration with hypoxia, clear infiltrate, fever resolves in 24h

— Answer: supportive care, no antibiotics — chemical pneumonitis, not pneumonia

— Stable HAP patient ready for SNF discharge on completion of IV antibiotics

— Answer: structured handoff with pending cultures, antibiotic stop date, follow-up plan

— Question offers daptomycin for MRSA pneumonia

— Answer: never — daptomycin is inactivated by surfactant

Key distinction: Step 3 frequently tests decision points at 48–72 hours (de-escalation, escalation if not improving, duration) rather than initial empiric choice — anchor your reasoning to those reassessment timepoints.

Stem pattern 1 — The "broaden empirically" trigger:

Stem pattern 2 — The de-escalation question:

Stem pattern 3 — MSSA pivot:

Stem pattern 4 — Cefepime neurotoxicity:

Stem pattern 5 — Non-resolving pneumonia:

Stem pattern 6 — Empyema:

Stem pattern 7 — Duration:

Stem pattern 8 — Aspiration with clear X-ray:

Stem pattern 9 — Transition of care:

Stem pattern 10 — Daptomycin trap:

One-Line Recap

HAP and VAP are nosocomial pneumonias requiring empiric broad-spectrum antibiotics tailored to MRSA risk, MDR Pseudomonas risk, and severity — followed by aggressive de-escalation at 48–72 hours and a 7-day total course in uncomplicated cases.

— MRSA risk? → add vancomycin or linezolid

— MDR Pseudomonas risk OR septic shock? → two anti-pseudomonal agents from different classes

— Otherwise → single anti-pseudomonal beta-lactam (pip-tazo, cefepime, meropenem, or levofloxacin)

— Obtain lower respiratory cultures (endotracheal aspirate preferred) and blood cultures before antibiotics, but never delay antibiotics in sepsis beyond 1 hour

— Reassess clinically and microbiologically at 48–72 hours — narrow to the most targeted active agent

— Treat for 7 days in uncomplicated disease; extend only for empyema, abscess, S. aureus bacteremia, or slow response

— Daptomycin is never used for pneumonia

— Vancomycin is inferior to cefazolin/nafcillin for MSSA — always pivot

— Cefepime in CKD can cause neurotoxicity — recognize and stop

— Anaerobic coverage is not routine for aspiration unless abscess/empyema

— HCAP is an obsolete category — do not treat nursing home residents reflexively with broad-spectrum agents

— Vaccinate (pneumococcal, influenza, COVID-19, RSV) before discharge

— Smoking cessation, swallow evaluation, medication reconciliation

— Repeat imaging at 6–8 weeks in patients ≥50 to exclude underlying malignancy

— Structured handoff to PCP/SNF with pending results and antibiotic stop date

Board pearl: If a Step 3 stem describes any HAP/VAP scenario, the highest-yield action is almost always one of three: start empiric coverage now within 1 hour, de-escalate based on culture data at 72 hours, or stop at 7 days — anchor every answer to those decision nodes.

The three-question empiric framework:

The non-negotiable management steps:

The trap-avoidance checklist:

The longitudinal Step 3 lens: